One of semaglutide's inactive ingredients has been linked to changes in gut bacteria and inflammatory markers. | Drug Discovery And Development ...

Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.

Eli Lilly (NYSE:LLY) received a positive regulatory opinion in Europe for Olumiant in adolescents with severe alopecia areata ...

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and ...

A pill version of the popular GLP-1 weight-loss drug Wegovy has been green-lit for use in the U.S. Here’s what that means for health care A new study finds that people who quit weight-loss medications ...

Novo Nordisk said on Monday it will invest 432 million euros (USD 506.43 million) to ‌expand ⁠its ⁠manufacturing facility in Athlone, Ireland."With the investment in the ...

A NOVEL non-peptide glucagon-like peptide-1 receptor agonist pill is more effective for weight loss than oral semaglutide in patients with Type 2 diabetes, a 2026 Phase III trial ...

Novo Nordisk (NVO) stock is in focus as Strive Pharmacy, a pharmacy partner for Hims & Hers (HIMS) plans to offer a compounded version of Wegovy pill. Read more here.

The new pill form of popular GLP-1 drugs contains a compound that could cause troubling side effects. Historically, ...

With a vital obesity launch now underway in the U.S., Novo Nordisk is casting its attention eastward as it shores up the prospects of its Wegovy pill in Europe and beyond.  | Novo will invest 432 ...

With Ozempic and Wegovy losing protection in key markets, Indian pharma majors gear up for launches that could sharply cut prices and expand access to diabetes and weight-loss therapy The world's ...

Both Novo and obesity market rival Eli Lilly have outlaid significant funds to ensure future demand for oral weight loss drugs is met.